КАНЦЕРОГЕННОСТЬ МАЛАТИОНА И ЭСТРОГЕНА НА ЭКСПЕРИМЕНТАЛЬНОЙ МОДЕЛИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ У КРЫС by G. Calaf M. & G. Calaf M.
DOI: 10.21294/1814-4861-2018-17-4-5-13
УДК: 618.19-006.6-02:577.175.6]-092.9
Для цитирования: Calaf G.M. Канцерогенность малатиона и эстрогена на экспериментальной модели рака молочной железы 
у крыс. Сибирский онкологический журнал. 2018; 17 (4): 5–13. – doi: 10.21294/1814-4861-2018-17-4-5-13.
For citation: Calaf G.M. Carcinogenicity of malathion and estrogen in an experimental rat mammary gland model. Siberian Journal 
of Oncology. 2018; 17 (4): 5–13. – doi: 10.21294/1814-4861-2018-17-4-5-13.
Канцерогенность малатиона и эстрогена 
на эКспериментальной модели раКа молочной 
железы у Крыс
G.M. Calaf1,2
Университет Тарапаки, Арика, Чили1
Арика, Авеню Сенадор Луис Валенте Росси, 1501. E-mail: gmc24@cumc.columbia.edu1
Центр радиологических исследований, Медицинский центр Колумбийского университета, 
г. Нью-Йорк, США2
США, 10032, г. Нью-Йорк, Западная 168-я улица, 6302
аннотация
Рак молочной железы является самой распространенной злокачественной опухолью среди женщин 
как в развитых, так и в развивающихся странах. Этиология рака молочной железы всё еще остается 
не до конца изученной. Химические вещества, такие как фосфорорганическое соединение – малатион 
(карбофос), используемый для борьбы с вредителями растений, являются этиологическими факторами 
для рака молочной железы. Связь между инициацией рака молочной железы и длительным воздействием 
эстрогена позволяет предпологать, что этот гормон может также играть этиологическую роль в этом про-
цессе. Тем не менее ключевые факторы, лежащие в основе формирования рака молочной железы, еще 
предстоит установить. Влияние таких субстанций, как малатион и эстроген, анализировалось в экспери-
ментальной модели молочной железы у крыс. Различные цитоплазматические белки играют ключевую 
роль в превращении нормальной клетки в злокачественную, и среди них есть семейство Ras-super и 
Ras-гомологичный A (Rho-A). Уровень этих белков был выше у животных, получавших малатион, чем у 
животных, получавших эстроген. E-кадгерины составляют большое семейство мембранных белков. ре-
зультаты исследования показали, что экспрессия E-кадгерина и виментина была выше, чем экспрессия 
белков c-Ha-ras и Rho-A у крыс, получавших эстрогены. При раке молочной железы иммуногистохими-
ческий анализ является важным компонентом рутинных патологических исследований и играет суще-
ственную роль в диагностической и прогностической оценке тяжести заболевания. целью настоящего 
исследования было выявление прогностических маркеров для пациентов с раком молочной железы.
Ключевые слова: канцерогенез, крысы, молочная железа, малатион, эстроген, этиология, белки.
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Abstract
Breast cancer is considered a major and common health problem in both developing and developed countries. 
The etiology of breast cancer, the most frequent malignancy diagnosed in women in the western world, has 
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Introduction
Breast cancer is considered a major and common 
health problem in both developing and developed 
countries. The etiology of breast cancer, the most fre-
quent malignancy diagnosed in women in the western 
world, has remained unidentified. The initiation and 
progression of breast cancer follows a complex mul-
tistep process that depends on various endogenous 
(hormonal imbalances, proliferative lesions, inherited 
mutations) and exogenous (diet, smoking, radiation, 
chemical exposures as pesticides) factors [1, 2]. Some 
of them are widely used with a huge potential for hu-
man exposure. Environmental factors are considered 
to be among the major influencing components causing 
increase in the incidence of breast cancer risk [3]. An 
important but unclarified question is the effect that 
environmental substances may play in the neoplastic 
process. Epidemiological studies have demonstrated 
the association between cancer in humans and agri-
culture pesticide exposure [4, 5].
Breast cancer models, where normal human breast 
epithelium cells undergo stepwise transformation into 
malignant cells after treatment with several agents 
provide the opportunity to understand the cellular and 
molecular mechanisms involved in breast carcinogen-
esis. Knowledge of factors that control cell prolifera-
tion of normal and neoplastic mammary epithelium, 
and the molecular basis of such action, is essential for 
a deeper understanding of the progression of human 
breast cancer. In rat mammary gland models whereby 
individual neoplastic transformed stages can be dis-
sected and studied provide an excellent opportunity to 
address cellular and molecular mechanisms involved in 
environmental-induced mammary carcinogenesis [6].
Experimental studies have shown that environmen-
tal substances (e.g., DDT, polychlorinated biphenyls, 
4-nonylphenol,4-octylphenol) seem to be involved in 
the etiology of breast cancers and can promote mam-
mary cancer [7, 8]. Such substances have been associ-
ated with the use of organophosphorous insecticides 
in agriculture and in non-occupational situations as 
exposure to contaminated clothing, soil, ground and 
surface water, as well as drifts from aerial spraying of 
pesticides [9-11] and it also has been associated with 
prolonged exposure to female hormones [12].
Chemicals as the organophosphorous pesticide 
malathion (M) have been used to control a wide 
range of sucking and chewing pests of field crops, 
and are involved in the etiology of breast cancers 
[13]. The association between breast cancer initiation 
and prolonged exposure to estrogen (E) suggests that 
this hormone may also have an etiologic role in such 
a process. However, the key factors behind the initia-
tion of breast cancer remain to be elucidated. Studies 
have found an association between human cancer and 
exposure to agricultural pesticides as demonstrated by 
IARC [4, 5].
An adequate animal model system has been devel-
oped to study the morphological changes that occur 
during mammary gland carcinogenesis. Mammary 
gland development is an attractive experimental ani-
mal model for understanding the effect of carcinogens 
since cell is not a random event, but is related to the 
topography of the mammary parenchyma and changes 
affected by age, hormonal variations and parity history. 
The structure of a normal rat mammary gland is com-
posed of a single primary or main lactiferous duct that 
branches into alveolar buds (ABs) and secondary ducts 
that are narrow and straight and end in small club-
shaped terminals, called terminal end buds (TEBs) that 
are equivalent to the terminal ductal lobular unit in the 
human breast, considered the site of origin of human 
breast carcinomas [14, 15]. The susceptibility of the 
mammary gland to M alone and in the presence of E 
was previously analyzed in an established rat mam-
mary gland model already reported [2, 12].
The Ras super family and Ras homologous A 
(Rho-A) have been shown to promote both cell prolif-
eration and cell invasion [16, 17]. Genetic evolutionary 
changes may occur in a preferred sequence in solid 
tumors and among the steps in this sequences include 
c-Ha-ras oncogene over-expression in breast cancer 
[18, 19]. This oncogene plays an important role in the 
progression of mammary cancer. An over expression 
remained unidentified. Chemicals as the organophosphorous pesticide malathion have been used to control 
a wide range of sucking and chewing pests of field crops, and are involved in the etiology of breast cancers. 
The association between breast cancer initiation and prolonged exposure to estrogen suggests that this 
hormone may also have an etiologic role in such a process. However, the key factors behind the initiation 
of breast cancer remain to be elucidated. The effect of environmental substances, such as malathion and 
estrogen was analyzed in an experimental rat mammary gland model. different cytoplasmic proteins are key 
in the transformation of a normal cell to a malignant tumor cell and among these are the Ras super family 
and Ras homologous A (Rho-A). Both types of proteins were greater in animals treated with malathion than 
those with estrogens. E-Cadherins constitute a large family of cell surface proteins. Results showed greater 
expression of E-Cadherin and vimentin than c-Ha-ras and Rho-A in rats treated by estrogens. In breast 
cancer, analysis using immunohistochemical markers is an essential component of routine pathological 
examinations, and plays an important role in the management of the disease by providing diagnostic and 
prognostic strategies. The aim of the present study was to identify markers that can be used as a prognostic 
tool for breast cancer patients.
Keywords: carcinogenesis, rat, mammary gland, malathion, estrogen, etiology, proteins.
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of mutated c-Ha-ras oncogene has been previously 
reported in 10% of breast cancer patients [18]. The Ras 
gene has been reported to be involved in chemically 
induced mammary carcinomas, in breast cancer cell 
lines, and in primary breast cancers, in which point 
mutations, loss of heterozygosity are present [20].
Accumulating data indicate that Rho-A protein-
dependent cell signaling is important for malignant 
transformation [21-23]. Once activated, Rho-A triggers 
a complex set of signal transduction pathways. Rho-A 
is over-expressed during tumorigenesis [24]. Authors 
[25] examined several breast cancers and found that 
the over-expression of Rho-A is involved in human 
carcinogenesis. All breast tumors analyzed contained 
large amounts of Rho-A protein, whereas was hardly 
found in adjacent normal tissue. Breast cancer progres-
sion from grade I to grade III, classification of World 
Health Organization (WHO) was accompanied by a 
significant increase in Rho-A protein levels.
E-cadherins constitute a large family of cell sur-
face proteins, including E (epithelial), N (neural), VE 
(vascular endothelial), P (placental), R (retinal) and 
K (kidney) cadherins [26]. Classical cadherins are 
single-pass transmembrane proteins which participate 
in Ca2+-dependent cell adhesion that is necessary to 
form solid tissues [27, 28]. E-cadherin is functionally 
linked to the generation of a polarized epithelial phe-
notype [29, 30]. The extracellular region of E-cadherin 
extends from the cell surface and binds to cadherins 
present on adjacent cells [31] whereas its intracellular 
region contains binding sites to interact with catenins 
and other regulatory proteins [32].
Different cytoplasmic proteins are important in 
the transformation of a normal cell to invasive tumor 
cell and among them is the vimentin. It is a 57-kDa 
intermediate filament protein which forms a part of the 
cytoskeleton. It is one of the cytoplasmic intermediate 
filament proteins, which are the major components 
of the cytoskeleton normally found in embryonic or 
mesenchymal stem cells [33, 34].
The aim of the present study was to evaluate Ras, 
Rho-A, E-Cadherin and Vimentin protein expression 
by immunohistochemistry in a transformed rat model 
induced by an environmental substance as malathion 
and an endogenous substance as estrogen to provide 
evidences that it can be used as good a prognostic tool 
for breast cancer patients.
Materials and Methods
Experimental designs: Thirty-nine-day-old virgin 
female Sprague-Dawley rats were obtained from the 
Catholic University of Chile (Santiago, Chile) and 
housed and bred in a barrier animal facility operated 
in accordance with the standards outlined in Guide 
for the Care and Use of Laboratory Animals [35]. All 
animals were allowed continuous access to a standard 
laboratory chow diet (Champion, Santiago, Chile). 
Experimental design: i) control group received saline 
solution, 250 μg/100 g body weight. Treated animals 
were injected subcutaneously (s.c.) for 5 days, twice 
a day with: ii) malathion (M) (Fyfanon TM, Chemi-
nova, Denmark) that received 22 mg/100 g bw, iii) 
17β-estradiol (E) (Sigma-Aldrich Chemical Co., Mil-
waukee, USA), 30 μg/100 g bw and iv) combination of 
both (M+E). The LD50 values of the substances were 
1.000 mg/kg. However, the dose used in these experi-
ments was 1/6th of the LD50 for M, which allowed a 
100% survival of animals after a 5-day treatment [2]. 
Animals were housed three per cage and palpated 
weekly to detect formation of tumors and sacrificed 
after 400 days following a 5-day treatment. Animals 
to be sacrificed were anesthetized by intraperitoneal 
injections of sodium pentobarbital (8 mg/100 g bw) 
and opened by a midline incision from the pubis to the 
sub-maxillary area to remove the tissues. 
Immunohistochemistry 
Mammary glands and palpable tumors were fixed 
in 10% neutral buffered, embedded in paraffin, then 
serially sectioned at a thickness of 5 μ and stained 
with hematoxylin-eosin (HE). Rat mammary gland 
tissues were excised to analyze protein expression by 
immunohistochemistry. Tissues were analyzed using 
a binocular microscope (Olympus CX31) with lens of 
10 x in which a 1-mm2 grid was installed in one of the 
oculars. The localization of the antibody was visual-
ized using 3, 3’-diaminobenzidine tetrahydrochloride 
(DAB) and counterstaining with Mayer’s hematoxylin 
(Sigma-Aldrich Chemical Co., Milwaukee, USA). 
All samples investigated were tested for anti-mouse 
monoclonal or polyclonal antibodies: H-Ras (mouse, 
sc-29), Rho-A (sc-418), E-Cadherin (mouse, sc-8426) 
and Vimentin (sc-6260) (all from Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA). Immuno peroxi-
dase staining of protein expression in the slides after 
treatment with pesticide and estrogen were examined 
in 10 fields of microscope. Five slides were counted 
per animal to determine per mm2 the number of stained 
proliferative ducts and lobules filled with hyaline 
casts in the mammary gland from control and treated-
animals. Fifty ducts in stage of proliferation (dsp/mm2) 
and fifty lobules filled with secretion were counted. 
Such results were scored according to scale from 0 
to 30 points. The ratings were: none (0 points), weak 
(10 points), slight (15 points), moderate (20 points) 
and intense (30 points) protein expression. Structures 
were graded as 0 when morphology of normal structure 
was present and there was not proliferative ducts and 
lobules with hyaline casts in the center of the struc-
tures. Immunochemical data were expressed as the 
average ± standard error (SE) of the mean. Statistical 
comparison between groups and controls were made 
by ANOVA and Dunnet´s test with P<0.05 between 
groups was considered to be significant.
Results
Analysis of stage for treatment of breast cancer 
by using markers of immunohistochemistry remains 
an essential component of routine pathological 
8 SIBERIAN JoURNAL oF oNCoLoGY. 2018; 17(4): 5–13
LAbORATORY AND EXPERIMENTAL STuDIES
examinations, and plays an important role in the 
management of the disease by providing diagnostic 
and prognostic strategies. The evaluation of Ras, 
Rho-A, E-Cadherin and Vimentin protein expression 
by immunohistochemistry in a rat mammary gland 
cancer model of transformed cells by pesticides in the 
presence of hormones as estrogens gave us evidences 
that they can be used as a good prognostic tool for 
breast cancer patients.
We have previously reported a synergism in the type 
of structures by the effect of M and E in the structures 
present in rat mammary gland development by using 
morphological measurements [13]. In the present study 
such effect was confirmed by immunohistochemistry 
by determining Ras, Rho-A, E-Cadherin and Vimentin 
protein expression. Results indicated that M induced 
significantly (p > 0.05) higher number of ducts in 
stage of proliferation per mm2 in mammary glands 
and had significantly greater (P<0.05) c-Ha-ras (Figure 
1A), Rho-A (Figure 1B), E-Cadherin (Figure 1C) and 
Vimentin (Figure 1D) protein expression at 400 days 
after a 5-day treatment in comparison to control, E and 
M+E treated rats, as seen in graphs. Figure 1E shows 
relative protein expression determined by peroxidase 
staining and correspond to M+E-treated animals 
on similar proteins where there was significantly 
(P<0.05) greater c-Ha-ras and Rho-A than Cadherin 
and Vimentin expression. 
Representative images of cross section of mammary 
gland immunostained with c-Ha-ras (Figure 2 B a-e), 
Rho-A (Figure 2 C a-e), E-Cadherin (Figure 2D a-e) 
and Vimentin (Figure 2E a-e) protein expression 
are seen. It can be observed that the control rats had 
normal mammary gland duct formation. A normal 
duct is shown in Figure 2 A a). Cross section of ducts 
in stage of proliferation can be seen in M-treated 
animals. Figure 2A b-d) represents ducts in stage of 
proliferation of M-treated rat stained with HE. Figure 
2A e) corresponds to a cross section of a tumor formed 
in animal treated with M. 
The relative c-Ha-ras, Rho-A, E-Cadherin and 
Vimentin protein expression in lobules can be seen in 
Figure 3A-D. Graphs correspond to the quantification 
of mammary glands of rats treated with E on relative 
average number of lobules with casts in stage of 
proliferation/mm2 in immune-stained cells. It was 
studied the effect of control, malathion (M), estrogen 
(E) and combination of both on relative protein 
Figure 1. Effect of control, 
malathion (M), estrogen (E) 
and combination of both on 
relative protein expression 
determined by peroxidase 
immune-staining in cross 
sections of rat mammary 
gland tissues and tumors 
derived from such animals: 
Graphs correspond to the 
quantification of relative 
average number of ducts in 
stage of proliferation (dsp/
mm2) in sections immune-
stained with: i) Malathion on: 
A) c-Ha-ras, B) Rho-A, C) 
E-Cadherin and d) Vimentin, 
and ii) Malathion+Estrogen 
on similar proteins. E) 
Graph corresponds to 
Malathion+Estrogen-treated 
animals on similar proteins 
where c-Ha-ras and Rho-A 
expression was greater than 
Cadherin and Vimentin 
(p<0.05)
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Figure 2. Representative 
images of cross section of 
rat mammary gland tissues 
and tumors stained with 
hematoxin and eosin) 
(2A a-e) and immune-
peroxidase stained. Effect 
of M on: c-Ha-Ras 
(2B a-e), Rho-A (2C a-e), 
E-Cadherin (2d a-e) and 
Vimentin (2E a-e) protein 
expression
Figure 3. Effect of control, 
malathion (M), estrogen (E) 
and combination of both on 
relative protein expression 
determined by peroxidase 
immune-staining in cross 
sections of rat mammary 
gland tissues and tumors 
derived from such animals: 
Graphs correspond to 
the to the quantification 
of mammary glands of 
rats treated on relative 
average number of lobules 
with casts in stage of 
proliferation/mm2 immune-
stained with i) A) c-Ha-ras, 
B) Rho-A, C) E-Cadherin 
and d) Vimentin protein 
expression in control, 
M, E and combination of 
both-treated- group. ii) 
E) Graph corresponds 
to Malathion+Estrogen-
treated animals on similar 
proteins where Cadherin 
and Vimentin expression 
was greater (p<0.05) than 
c-Ha-ras and Rho-A
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Figure 4. Representative 
images of cross section 
of rat mammary gland 
tissues and tumors stained 
with hematoxin and eosin) 
(4a-e) and immune-
peroxidase stained. Effect 
of E on: c-Ha-Ras (4B 
a-e), Rho-A (4C a-e), 
E-Cadherin (4d a-e) and 
Vimentin (4E a-e) protein 
expression
Figure 5. Representative 
images of cross section 
of rat mammary gland 
tissues and tumors stained 
with hematoxin and eosin) 
(4a-e) and immune-
peroxidase stained. Effect 
of M and E on: c-Ha-Ras 
(5B a-e), Rho-A (5C a-e), 
E-Cadherin (5d a-e) and 
Vimentin (5E a-e) protein 
expression
expression determined by peroxidase immune-staining 
in cross sections of rat mammary gland tissues and 
tumors derived from such animals. Results showed 
that E significantly (P<0.05) increased the number 
of lobules filled with casts parallel to greater of A) 
c-Ha-ras, B) Rho-A, C) E-Cadherin and D) Vimentin 
protein expression than control, M, E and combination 
of both-treated- group at 400 days after a 5-day 
treatment in comparison to controls, M and M+E 
combined. In Figure 4A a can be seen that the control 
rat mammary tissue presented a single main lactiferous 
duct that branches into smaller ducts from which TEBs 
and ABs are formed. Figure 4A b) shows a normal 
mammary gland lobule. Cross section of lobules of 
mammary glands of E-treated rat stained with HE can 
be seen in Figure 4A c-d. Figure 4A e corresponds to 
a cross section of a tumor formed in animal treated 
with E. Figure 1E shows relative protein expression 
determined by peroxidase staining and correspond 
to M+E-treated animals on similar proteins where 
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E-Cadherin and Vimentin was significantly (P<0.05) 
greater than c-Ha-ras and Rho-A expression. 
Cross section of mammary glands of M+E-treated 
rat and stained with HE can be seen in Figure 5A a-d). 
Figure 5A e) corresponds to a tumor formed in animal 
treated with M+E. Results indicated that mammary 
glands of such animals showed numerous lobules 
with secretion or casts in stage of proliferation as well 
as ducts in stage of proliferation parallel to c-Ha-ras 
(Figure 5B), Rho-A (Figure 5C), E-cadherin (Figure 
5D) and Vimentin (Figure 5E) protein expression at 
400 days after a 5-day treatment in comparison to 
controls, E and M. The relative c-Ha-ras, Rho-A, 
E-Cadherin and Vimentin protein expression in 
ducts in stage of proliferation and lobules can be 
seen in graphs of Figures 5A-D. Figure 5E shows 
relative protein expression determined by peroxidase 
staining and correspond to M+E-treated animals on 
similar proteins where E-Cadherin and Vimentin 
was significantly (P<0.05) greater than c-Ha-ras and 
Rho-A expression. Cross section of ducts in stage 
of proliferation and lobules filled with secretion 
can be seen in M+E-treated animals. Figure 5A a-d) 
stained with HE. Figure 5A e) corresponds to a tumor 
formed in animal treated with M+E. Representative 
images of cross section of mammary gland of these 
animals immunostained with c-Ha-ras (Figure 5B 
a-e), Rho-A (Figure 5C a-e), E-Cadherin (Figure 5D 
a-e) and Vimentin (Figure 5E a-e) protein expression 
are seen.
Discussion
The evaluation of Ras, Rho-A, E-Cadherin and 
Vimentin protein expression by immunohistochemistry 
in this transformed model induced by pesticides as 
malathion and an endogenous substances as estrogen 
provided evidence that it can be used as good a 
prognostic tool for breast cancer patients. The ducts 
markedly increased in size and number of cells per 
mm2. Furthermore, such structures increased until 
tumors started to appear with similar type of cells 
and after 400 days of pesticide of 5 day treatment 
those structures were referred to as proliferative 
ducts. M alone induced changes exclusively at the 
level of ducts that increased in size and number of 
cells per mm2, these were defined as ductal in stage 
of proliferation (dsp/mm2) and the interesting finding 
was that as time progressed those structures were 
transformed in mammary gland tumors that revealed a 
similarity to ductal carcinomas as described by WHO 
[15] in comparison to controls. Sections of the ducts 
were filled with increased number of cells with dark 
nucleus. 
E induced significant progressive alterations in 
lobules in comparison to control in the rat mammary 
gland after 400 days of the 5-day treatment. Congested 
tubules were filled with pink eosinophylic deposits. 
Furthermore, such structures increased in number per 
mm2 and also in size until tumors started to appear. 
E-treated rats showed that the density of the number 
of terminal end buds per mm2 decreased as time 
progressed and lobules became markedly abnormal, 
while large and dilated congested structures increased 
in size and number per mm2. Results indicated that 
E alone increased the average number of lobules per 
mm2 of rat mammary glands in comparison to control 
and M treatment alone at 400 days after a 5-day 
treatment. Such structures were referred to as secretory 
lobules since they were congested tubules filled with 
pink deposits until lobular carcinomas started to 
appear and revealed that the tumors originated were 
pathologically similar to lobular carcinomas according 
to WHO [15]. Mammary gland of E-treated animal 
had altered lobules full of hyaline casts; the control 
rats had normal lobule formation. The increase in the 
number of secretory lobules was higher in the E-treated 
animals after 400 days of the 5-day injections than in 
the other treated group. Lobules increased in size with 
the time and mammary gland tumors were induced by 
the effect of E alone. 
Environmental endocrine disrupting chemicals, 
including pesticides and industrial chemicals, are also 
considered among the environmental agents that are 
released into the environment producing deleterious 
effects on wildlife and humans. Lacassagne in 1932 
[36] was the first to demonstrate that the administration 
of estrogens to experimental animals increased the 
incidence of mammary cancer, indicating at the 
same time that sex hormones were involved in the 
development of neoplasias and their progression in 
hormone-target organs such as the prostate and the 
breast. This knowledge was soon applied to cancer 
treatment [13].
Combination of M+E induced greater cellular 
changes in the rat mammary glands than E or M alone 
in comparison to control animals after 400 days of the 
5-day treatment. Increased amount of proliferative 
ducts and secretory lobules were induced by these 
two substances showing rat mammary gland tumor 
formation. Mammary gland tumor formed by the 
effect of these substances was characterized by the 
presence of both types of structures as ducts in stage 
of proliferation and secretory lobules [13].
Our studies showed that M induced greater c-Ha-ras 
protein expression in ducts in proliferative stage at 400 
days after a 5-day treatment in comparison to control, 
E and M+E treated rats. High c-Ha-Ras expression in 
intraductal proliferative lesions is very relevant since 
these epithelial lesions have a risk of progression to 
invasive breast cancer and related issues, particularly 
atypical ductal hyperplasia [37]. However, the use of 
c-Ha-Ras expression as a diagnostic and prognostic 
marker should be selective and should preferably be 
used in conjunction with other markers. According to 
published data, the major value of c-Ha-Ras expression 
is in its clinical correlation with an improved prognosis 
of relapse [38-40]. Since Ras is often mutated in human 
cancers, much effort has been devoted to devising 
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means of controlling the activity of Ras [41]. Breast 
tumors have been shown to have an elevated expression 
of the Harvey Ras oncogene when compared to their 
respective normal tissue sections [42]. The Harvey Ras 
oncogene has also been shown to have a significant 
correlation with the clinicopathological characteristics 
of breast cancer [43]. Immunohistochemical analyses 
of Ras oncogene expression in human breast lesions 
have been carried out [44], as well as of the p21 Ras 
oncogene [45-47], with a high expression in breast 
cancer patients indicating clinical significance.
Our studies showed that E induced greater c-Ha-ras, 
Rho-A, Vimentin and E-Cadherin protein expression 
in lobules full of casts and secretion at 400 days 
after a 5-day treatment in comparison to control, E 
and M+E treated rats. Rho-A protein-dependent cell 
signaling is important for malignant transformation 
[21-23]. Once activated, Rho-A triggers a complex 
set of signal transduction pathways. Rho-A is over-
expressed during human carcinogenesis [24, 48]. M 
also induced greater Vimentin protein expression that 
paralleled neoplastic cells with metastatic properties, 
including breast cancer cells as we have previosly 
reported in breast cancer patients [49]. E-Cadherins 
that constitute a large family of cell surface proteins 
was altered by these substances and its expression 
was greater than control. It can be concluded that Ras, 
Rho-A, E-Cadherin and Vimentin are good marker 
to be used in breast cancer patients and to predict 
response to therapy in such patients.
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